E28 Literaturhinweise und Internetadressen
1 Internistische Tumortherapie


2 Supportive Therapie

2.1 Antiemese


2.2 Schmerztherapie

2.3 Substitutionstherapie

2.4 Maligne Ergüsse

2.5 Psychoonkologie und psychiatrische Störungen bei Krebskran ken

2.6 Fertilitätserhaltende Maßnahmen
3 Stammzelltransplantation


4 Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen


Internetadressen
http://www.dgho-infektionen.de/agiho/content
http://www.idsociety.org
http://www.ichs.org

5 Tumor- und therapiassoziierte Notfälle
http://www.onkosupport.de

6 Anämien
7 Aplastische Anämien


**Internetadressen**

http://www.dgho.de (Therapieempfehlungen der DGHO)
http://www.aplastische-anaemie.com (Deutsche Studiengruppe Aplastische Anämie)
http://www.aamds-international.org (Aplastic Anemia International Foundation)
http://www.aplastische-anaemie.de (Aplastische Anämie e. V.)

**7.2 Isolierte aplastische Anämie**


**8 Akute Leukämien**


Bene MC, Bernier M, Casasnovas RO et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The


### 9 Myelodysplastic Syndrome (MDS)


Bennett JM, Catovsky D, Daniel TM et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic


de Witte T, Suciu S, Verhoef G et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326–2331.


Internetadressen
http://www.mds-foundation.org (MDS-Foundation)
http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/mds (MDS-Leitlinien)
http://www.mds-register.de/mdsstudien
http://www.kompetenznetz-leukaemie.de/content/aerzte/studien/studienregister/index_ger.html

10 Chronische myeloproliferative Neoplasien (CMPN)


11 Hodgkin-Lymphom


12 Indolente (niedrig maligne) Non-Hodgkin-Lymphome


Indolente (niedrig maligne) Non-Hodgkin-Lymphome


Eichhorst B, Fink AM, Busch R et al. Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international randomized study of the German CLL Study Group. Blood (ASH Annual Meeting Abstracts #526) 2013.


Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 112 (2008) 125 (abstract 325).


Horn H, Schmelter C, Leich E et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 96 (2011) 1,327–1,334.


Knauf WU, Langenmayer I, Ehlers B et al. Serum levels of soluble CD23, but not of soluble CD25 are predictive for disease progression in early stage B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 27 (1997) 523–532.


Morschhauser F, Radford J, Van Hoof A et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International,
13 Aggressive (hoch maligne) Non-Hodgkin-Lymphome


### 14 Plasmazellneoplasien


15 Malignome des Respirationstrakts


Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of pacli-


Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 rando-

16 Malignome des Kopf- und Halsbereichs


Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 rando-


Zhong LP, Zhang CP, Ren GX et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus...
17 Malignome des Gastrointestinaltrakts

17.1 Ösophaguskarzinom


17.2 Magenkarzinom


17.3 Pankreaskarzinom


Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancre-


Chiorean EG, Von Hoff DD, Ervin TJ et al. CA19–9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 31 (Suppl) (2013) Abstr. 4058.


Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Therapeutic Advances in Medical Oncology 5 (1) (2013) 81–89.


Moore MJ, Von Hoff DD, Ervin TJ et al. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31 (2013) (suppl; abstr. 4059).

Mukherjee S, Hurt C, Griffiths G et al. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC). J Clin Oncol 30 (2012) (suppl 34; abstr LBA146).


17.4 Cholangiozelluläres und Gallenblasenkarzinom


17.5 Hepatozelluläres Karzinom


17.7 Kolorektales Karzinom

17.8 Analkarzinom


18 Malignome des Urogenitaltrakts


Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced


de Bono JS, Logothetis CJ, Fizazi K et al. Abiraterone Acetate (AA) plus low dose prednisone (p) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (Chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Annals of Oncol 21 (2010) Suppl. 8.


Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors


Sammler C, Beyer J, Bokemeyer C et al. Risk factors in germ cell tumor patients with relapse or progressive disease after first-line chemotherapy: evaluation of a


19 Mammakarzinom und gynäkologische Malignome

19.1 Mammakarzinom


19.2 Ovarialtumoren


Katsumata N, Yasuda M, Isonishi S et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG


Wagner U, Marth C, Largillier R et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs pac-


19.3 Zervixkarzinom


19.4 Endometriumkarzinom


20 Tumoren der Haut

Atkins MB, Lee S, Flaherty LE et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with ciplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic


Literaturhinweise und Internetadressen


Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds.) WHO Classification of Tumours of Soft Tissue and Bone. IARC: Lyon 2013


Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma


22 Malignome endokriner Organe

22.1 Schilddrüsenkarzinom


Cooper DS, Specker B, Ho M et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8 (1998) 737–744.


**22.2 Tumoren der Nebenniere**


22.3 Neuroendokrine Neoplasien (NEN) des gastroenteropankreatischen Systems


Literaturhinweise und Internetadressen


Literaturhinweise und Internetadressen

23 Malignome unbekannter Primärlokalisierung


24  Malignome des zentralen Nervensystems (ZNS)


Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective


### 25 HIV-assoziierte Malignome


**Internetadressen**

http://www.kompetenznetz-leukaemie.de
http://www.lymphome.de
http://www.nccn.org
http://www.kompetenznetz-hiv.de
http://www.hivbuch.de
http://www.hopkins-aids.edu
http://www.hivguidelines.org

---

**26 Hämorrhagische Diathesen**


Literaturhinweise und Internetadressen


27 Thrombophilie, thrombembolische Erkrankungen und antithrombotische Therapie


